<p>随着美国股市在波动期中航行，主要指数因对人工智能泡沫的担忧和即将发布的经济数据而收盘下跌，投资者正在探索多样化的机会。便士股票通常与较小或较新的公司相关，提供了一条独特的投资途径，结合了可负担性和潜在增长。尽管被视为过时的术语，这些股票仍然通过提供进入可能具有强大财务状况和增长潜力的公司的机会而保持相关性，且价格较低。</p>
<h3>美国十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.05</td>
<td>$179.57M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.16</td>
<td>$531.71M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.76</td>
<td>$178.24M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$4.97</td>
<td>$56.35M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$589.37M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8701</td>
<td>$6.32M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.05</td>
<td>$91.76M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国便士股票筛选器的 342 只股票的完整列表。</p>
<p>我们将查看筛选工具中的一些最佳选择。</p>
<h2>Oramed Pharmaceuticals (ORMP)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Oramed Pharmaceuticals Inc. 专注于利用技术平台进行治疗性蛋白质的口服递送的制药解决方案的研究与开发，市值约为 1.2259 亿美元。</p>
<p><strong>运营：</strong> Oramed Pharmaceuticals Inc. 尚未报告任何具体的收入细分。</p>
<p><strong>市值：</strong> $122.59M</p>
<p>Oramed Pharmaceuticals Inc. 以 1.2259 亿美元的市值在便士股票领域中呈现出引人注目的案例，因其强大的财务状况和近期的盈利能力。该公司无债务，短期资产为 1.361 亿美元，足以覆盖短期和长期负债。在过去一年中，Oramed 的收益激增了 882.1%，显著超过行业平均水平，同时保持了 2.8 倍的低市盈率，而美国市场的市盈率为 19 倍。尽管收入来源有限（200 万美元），其战略性权利协议和分红声明显示出对未来增长前景的信心。</p>
<ul>
<li>点击这里了解 Oramed Pharmaceuticals 的细微差别，查看我们的详细分析财务健康报告。</li>
<li>在这里了解 Oramed Pharmaceuticals 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis"/></p>
<p>ORMP 财务状况分析截至 2025 年 12 月</p>
<h2>Smart Sand (SND)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Smart Sand, Inc. 为压裂砂客户提供从矿山到井场的支撑剂供应和物流解决方案，市值为 1.7461 亿美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自其砂石部门，贡献了 3.3132 亿美元，另外还有 416 万美元来自 Smartsystems。</p>
<p><strong>市值：</strong> $174.61M</p>
<p>Smart Sand, Inc. 以 1.7461 亿美元的市值最近实现了盈利，报告第三季度收入为 9278 万美元，净收入为 300 万美元。该公司保持了 3% 的满意净债务与股本比率，并在过去五年中减少了债务。尽管股本回报率较低，仅为 1.6%，Smart Sand 的资深董事会和管理团队提供了稳定性，而短期资产超过了短期和长期负债。最近的公告包括特别现金分红和总计 2.55% 的股票回购，反映出在收益增长波动趋势中的股东价值倡议。</p>
<ul>
<li>通过阅读我们的资产负债表健康报告，深入了解 Smart Sand 的表现。</li>
<li>在我们的历史数据报告中探索 Smart Sand 的表现随时间的变化。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1a600d62-1eb4-47af-9fd5-a2ed7cf24239/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1a600d62-1eb4-47af-9fd5-a2ed7cf24239/chart/debt-equity-history-analysis"/></p>
<p>SND 债务与股本历史及分析截至 2025 年 12 月</p>
<h2>MariMed (MRMD)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> MariMed Inc. 从事在美国和国际上种植、生产和销售品牌大麻产品，市值为 4352 万美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自其品牌大麻产品的种植、加工和销售，产生了 1.5738 亿美元的收入。</p>
<p><strong>市值：</strong> $43.52M</p>
<p>MariMed Inc. 以 4352 万美元的市值在充满挑战的便士股票市场中通过扩展产品线和市场覆盖面而努力。最近的举措包括推出新产品如 Bundle Up Betty's，并通过战略合作伙伴关系进入大麻衍生的 THC 市场，这可能增强品牌知名度。尽管这些努力，MariMed 仍然处于亏损状态，2025 年第三季度净亏损为 295 万美元，且在五年内亏损不断增加。该公司的高净债务与股本比率为 96.4%，带来了财务风险，尽管它受益于经验丰富的董事会和管理团队指导其战略前进。</p>
<ul>
<li>点击这里访问我们的完整财务健康分析报告，以了解 MariMed 的动态。</li>
<li>查看我们的增长表现报告，以获取 MariMed 未来的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0640a1e6-a59c-4488-ae69-5cd2a65eb2de/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0640a1e6-a59c-4488-ae69-5cd2a65eb2de/chart/debt-equity-history-analysis"/></p>
<p>MRMD 债务与股本历史及分析截至 2025 年 12 月</p>
<h2>关键要点</h2>
<ul>
<li>解锁更多宝藏！我们的美国便士股票筛选器为您挖掘了 339 家更多公司供您探索。点击这里揭开我们精心策划的 342 只美国便士股票名单。</li>
<li>寻找新视角？人工智能即将改变医疗保健。这 30 只股票正在从早期诊断到药物发现等各个方面努力。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前入场。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>移动基础设施用于国防和灾难应对</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达服务，随时随地。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

Oramed制药

<p>这篇文章强调了在美国市场波动中有前景的低价股，重点关注了 Oramed Pharmaceuticals、Smart Sand 和 MariMed。Oramed 的财务状况良好，市值为 1.2259 亿美元，且盈利增长显著。Smart Sand 的市值为 1.7461 亿美元，已实现盈利并宣布了股东价值倡议。MariMed 的市值为 4352 万美元，尽管面临财务挑战，仍在扩展其大麻产品线。文章强调了这些低价股的潜在增长和相关风险</p>

<p>As the U.S. stock market navigates a period of volatility, with major indexes closing lower amid AI bubble concerns and upcoming economic data releases, investors are exploring diverse opportunities. Penny stocks, often associated with smaller or newer companies, offer a unique investment avenue that combines affordability with potential growth. Despite being considered an outdated term, these stocks remain relevant by providing access to companies that may have strong financials and growth potential at lower price points.</p>
<div class="lb-trans"><p>随着美国股市在波动期中航行，主要指数因对人工智能泡沫的担忧和即将发布的经济数据而收盘下跌，投资者正在探索多样化的机会。便士股票通常与较小或较新的公司相关，提供了一条独特的投资途径，结合了可负担性和潜在增长。尽管被视为过时的术语，这些股票仍然通过提供进入可能具有强大财务状况和增长潜力的公司的机会而保持相关性，且价格较低。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美国十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.05</td>
<td>$179.57M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.16</td>
<td>$531.71M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.76</td>
<td>$178.24M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$4.97</td>
<td>$56.35M</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$589.37M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8701</td>
<td>$6.32M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.05</td>
<td>$91.76M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.05</td>
<td>$179.57M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.16</td>
<td>$531.71M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.76</td>
<td>$178.24M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$4.97</td>
<td>$56.35M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$589.37M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8701</td>
<td>$6.32M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.05</td>
<td>$91.76M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 342 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国便士股票筛选器的 342 只股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我们将查看筛选工具中的一些最佳选择。</p>
</div><h2>Oramed Pharmaceuticals (ORMP)</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals (ORMP)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Oramed Pharmaceuticals Inc. focuses on the research and development of pharmaceutical solutions utilizing a technology platform for the oral delivery of therapeutic proteins and has a market cap of approximately $122.59 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Oramed Pharmaceuticals Inc. 专注于利用技术平台进行治疗性蛋白质的口服递送的制药解决方案的研究与开发，市值约为 1.2259 亿美元。</p>
</div><p><strong>Operations:</strong> Oramed Pharmaceuticals Inc. has not reported any specific revenue segments.</p>
<div class="lb-trans"><p><strong>运营：</strong> Oramed Pharmaceuticals Inc. 尚未报告任何具体的收入细分。</p>
</div><p><strong>Market Cap:</strong> $122.59M</p>
<div class="lb-trans"><p><strong>市值：</strong> $122.59M</p>
</div><p>Oramed Pharmaceuticals Inc., with a market cap of US$122.59 million, presents an intriguing case in the penny stock realm due to its robust financial position and recent profitability. The company is debt-free, with short-term assets of US$136.1 million comfortably covering both short- and long-term liabilities. Over the past year, Oramed's earnings surged by 882.1%, significantly outpacing industry averages, while maintaining a low price-to-earnings ratio of 2.8x compared to the broader US market's 19x. Despite limited revenue streams (US$2 million), its strategic Rights Agreement and dividend declaration signal confidence in future growth prospects.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc. 以 1.2259 亿美元的市值在便士股票领域中呈现出引人注目的案例，因其强大的财务状况和近期的盈利能力。该公司无债务，短期资产为 1.361 亿美元，足以覆盖短期和长期负债。在过去一年中，Oramed 的收益激增了 882.1%，显著超过行业平均水平，同时保持了 2.8 倍的低市盈率，而美国市场的市盈率为 19 倍。尽管收入来源有限（200 万美元），其战略性权利协议和分红声明显示出对未来增长前景的信心。</p>
</div><ul>
<li>Click here to discover the nuances of Oramed Pharmaceuticals with our detailed analytical financial health report.</li>
<li>Learn about Oramed Pharmaceuticals' historical performance here.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里了解 Oramed Pharmaceuticals 的细微差别，查看我们的详细分析财务健康报告。</li>
<li>在这里了解 Oramed Pharmaceuticals 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis"/></p>
<p>ORMP Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>ORMP 财务状况分析截至 2025 年 12 月</p>
</div><h2>Smart Sand (SND)</h2>
<div class="lb-trans"><h2>Smart Sand (SND)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Smart Sand, Inc. offers mine to wellsite proppant supply and logistics solutions for frac sand customers, with a market cap of $174.61 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Smart Sand, Inc. 为压裂砂客户提供从矿山到井场的支撑剂供应和物流解决方案，市值为 1.7461 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Sand segment, contributing $331.32 million, with an additional $4.16 million from Smartsystems.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其砂石部门，贡献了 3.3132 亿美元，另外还有 416 万美元来自 Smartsystems。</p>
</div><p><strong>Market Cap:</strong> $174.61M</p>
<div class="lb-trans"><p><strong>市值：</strong> $174.61M</p>
</div><p>Smart Sand, Inc., with a market cap of US$174.61 million, has recently turned profitable, reporting third-quarter revenue of US$92.78 million and net income of US$3 million. The company maintains a satisfactory net debt to equity ratio of 3% and has reduced its debt over the past five years. Despite low return on equity at 1.6%, Smart Sand's seasoned board and management team provide stability, while short-term assets exceed both short- and long-term liabilities. Recent announcements include a special cash dividend and share buybacks totaling 2.55% under its repurchase plan, reflecting shareholder value initiatives amidst fluctuating earnings growth trends.</p>
<div class="lb-trans"><p>Smart Sand, Inc. 以 1.7461 亿美元的市值最近实现了盈利，报告第三季度收入为 9278 万美元，净收入为 300 万美元。该公司保持了 3% 的满意净债务与股本比率，并在过去五年中减少了债务。尽管股本回报率较低，仅为 1.6%，Smart Sand 的资深董事会和管理团队提供了稳定性，而短期资产超过了短期和长期负债。最近的公告包括特别现金分红和总计 2.55% 的股票回购，反映出在收益增长波动趋势中的股东价值倡议。</p>
</div><ul>
<li>Get an in-depth perspective on Smart Sand's performance by reading our balance sheet health report here.</li>
<li>Explore historical data to track Smart Sand's performance over time in our past results report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的资产负债表健康报告，深入了解 Smart Sand 的表现。</li>
<li>在我们的历史数据报告中探索 Smart Sand 的表现随时间的变化。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1a600d62-1eb4-47af-9fd5-a2ed7cf24239/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/1a600d62-1eb4-47af-9fd5-a2ed7cf24239/chart/debt-equity-history-analysis"/></p>
<p>SND Debt to Equity History and Analysis as at Dec 2025</p>
<div class="lb-trans"><p>SND 债务与股本历史及分析截至 2025 年 12 月</p>
</div><h2>MariMed (MRMD)</h2>
<div class="lb-trans"><h2>MariMed (MRMD)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> MariMed Inc. is involved in the cultivation, production, and sale of branded cannabis products both in the United States and internationally, with a market cap of $43.52 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> MariMed Inc. 从事在美国和国际上种植、生产和销售品牌大麻产品，市值为 4352 万美元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its cultivation, processing, and sale of branded cannabis products, generating $157.38 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其品牌大麻产品的种植、加工和销售，产生了 1.5738 亿美元的收入。</p>
</div><p><strong>Market Cap:</strong> $43.52M</p>
<div class="lb-trans"><p><strong>市值：</strong> $43.52M</p>
</div><p>MariMed Inc., with a market cap of US$43.52 million, is navigating the challenging penny stock landscape by expanding its product lineup and market reach. Recent initiatives include launching new products like Bundle Up Betty's and entering the hemp-derived THC market through strategic partnerships, which could enhance brand visibility. Despite these efforts, MariMed remains unprofitable with a net loss of US$2.95 million for Q3 2025 and increasing losses over five years. The company's high net debt to equity ratio of 96.4% poses financial risks, although it benefits from an experienced board and management team guiding its strategy forward.</p>
<div class="lb-trans"><p>MariMed Inc. 以 4352 万美元的市值在充满挑战的便士股票市场中通过扩展产品线和市场覆盖面而努力。最近的举措包括推出新产品如 Bundle Up Betty's，并通过战略合作伙伴关系进入大麻衍生的 THC 市场，这可能增强品牌知名度。尽管这些努力，MariMed 仍然处于亏损状态，2025 年第三季度净亏损为 295 万美元，且在五年内亏损不断增加。该公司的高净债务与股本比率为 96.4%，带来了财务风险，尽管它受益于经验丰富的董事会和管理团队指导其战略前进。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of MariMed.</li>
<li>Review our growth performance report to gain insights into MariMed's future.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整财务健康分析报告，以了解 MariMed 的动态。</li>
<li>查看我们的增长表现报告，以获取 MariMed 未来的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0640a1e6-a59c-4488-ae69-5cd2a65eb2de/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/0640a1e6-a59c-4488-ae69-5cd2a65eb2de/chart/debt-equity-history-analysis"/></p>
<p>MRMD Debt to Equity History and Analysis as at Dec 2025</p>
<div class="lb-trans"><p>MRMD 债务与股本历史及分析截至 2025 年 12 月</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>关键要点</h2>
</div><ul>
<li>Unlock more gems! Our US Penny Stocks screener has unearthed 339 more companies for you to explore.Click here to unveil our expertly curated list of 342 US Penny Stocks.</li>
<li>Searching for a Fresh Perspective? AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁更多宝藏！我们的美国便士股票筛选器为您挖掘了 339 家更多公司供您探索。点击这里揭开我们精心策划的 342 只美国便士股票名单。</li>
<li>寻找新视角？人工智能即将改变医疗保健。这 30 只股票正在从早期诊断到药物发现等各个方面努力。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前入场。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移动基础设施用于国防和灾难应对</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达服务，随时随地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

Oramed 制药及其他两个值得关注的有前景的便士股